|
GTF3C1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.47229999969412E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.86709999997026E-06 |
| Normal-vs-Stage2 |
9.468300E-02 |
| Normal-vs-Stage3 |
3.71470000315455E-08 |
| Normal-vs-Stage4 |
1.21650001183582E-09 |
| Stage1-vs-Stage2 |
2.163900E-02 |
| Stage1-vs-Stage3 |
6.487600E-02 |
| Stage1-vs-Stage4 |
1.998290E-03 |
| Stage2-vs-Stage3 |
8.015300E-04 |
| Stage2-vs-Stage4 |
6.12580000000085E-05 |
| Stage3-vs-Stage4 |
2.764400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.82570003138505E-09 |
| Normal-vs-AfricanAmerican |
9.498800E-03 |
| Normal-vs-Asian |
1.81650000041778E-07 |
| Caucasian-vs-AfricanAmerican |
3.119800E-01 |
| Caucasian-vs-Asian |
4.969800E-01 |
| AfricanAmerican-vs-Asian |
1.931760E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.60111999999435E-05 |
| Normal-vs-Female |
1.44329999951509E-07 |
| Male-vs-Female |
5.367600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.42800000397281E-08 |
| Normal-vs-Age(41-60Yrs) |
3.0213000001833E-07 |
| Normal-vs-Age(61-80Yrs) |
4.01190000000051E-05 |
| Normal-vs-Age(81-100Yrs) |
8.977200E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.946200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.308000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.496400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.057400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.841600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.012800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.92188536991034E-12 |
| Classical-VS-Follicular |
4.22379999975853E-07 |
| Classical-VS-Other |
3.734400E-02 |
| Classical-VS-Normal |
5.79949976931005E-10 |
| Tall-VS-Follicular |
2.66453525910038E-15 |
| Tall-VS-Other |
3.314800E-01 |
| Tall-VS-Normal |
1.63258295771129E-12 |
| Follicular-VS-Other |
1.77415000000014E-05 |
| Follicular-VS-Normal |
5.704800E-01 |
| Other-VS-Normal |
2.96779999997554E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.497320E-03 |
| Normal-vs-N1 |
3.88100662718216E-12 |
| N0-vs-N1 |
4.76509998126318E-09 |
|
|
